A novel non-invasive glucose monitor to improve global diabetes care

Millions of diabetics world-wide need to monitor or control their glucose level in order to avoid complications by the decease. The main issue for the diabetics is to avoid hypoglycemia (low glucose level) and hyperglycemia (high glucose level). At present this is done by pricking the finger and applying a drop of blood on a strip on a hand held instrument. Apart from being painful and indiscreet, the readings are not continuous. Thus the holy grail has been to be able to develop a continuous non-invasive glucose sensor which at all time can tell the diabetic his or her glucose level whereby action can be taken before the glucose level meet dangerous levels. The sensor will be located on the body by a patch and the readings will be sent to a smart phone for presentation of the readings and alarms. Mecsense AS located at Oslo Innovation Centre is developing a continuous and non-invasive glucose indicator for diabetics based on a newly discovered principle for density and viscosity measurements in cooperation with Mid Sweden University, Emzense AB and ShortLink AB in Sweden and Noliac AS in Denmark. The density of the body liquids and viscosity caused by variations of the glucose level are measured by a novel physical principle protected by two patent applications. The first application is granted in Australia, China, USA, Israel and Norway and is approved in Japan and Russia. The second application is pending in Brazil, Canada and Europe (including ca. 35 countries). The principle has been verified in controlled environment conditions in laboratory and in-house pilot studies on humans with a deviation from blood taken readings of less than 15%. The objective of Mecsense now is to perform a number of in-vitro tests on biological liquid with varying carbohydrates, lipids et and build a limited number of sensors for clinical trials at well perpetuated hospitals in Scandinavia. During 2016 PZT elements with different frequencies have been optimized by tests in sugar solutions and humans with promising results and the optimal frequency have been found. The design of the electronics are now completed and we have built 3 stationary unit where 6 sensors can be tested on different part on the body to find optimal location. The first sensors are expected to be available at the end of 2018. This is a project supported by NFR, Innovation Norway, Oslo MedTech and SkatteFun

Development of a continuous and non-invasive sensor the measurement of the glucose level in diabetics based on a new physical princple for detection of minute changes of body fluid density caused by varying glucose. The research will consists of: Mathematical modelling of the principle for understaning of the physical principle behind this. Development of electronics and production of 3 stationary sensors for in-house clinical studies and testing on animals. Engineering and development of a limited number of portable sensors for clinical tests at hospitals. Engineering the final sensor with miniatyrized electronics and communication to a smart phone. Development of AP for presentation of the data on the smart phone. CE and FDA approvals. Clinical trials at hospitals.